John S Clemmer1, Tariq Shafi1,2, Yoshitsugu Obi3. 1. Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA. 2. Division of Nephrology, University of Mississippi Medical Center, 2500 North State Street, Suite L-504, Jackson, MS, 39216, USA. 3. Division of Nephrology, University of Mississippi Medical Center, 2500 North State Street, Suite L-504, Jackson, MS, 39216, USA. yobi@umc.edu.
Abstract
PURPOSE OF REVIEW: In this article, we summarize recent advances in understanding hypertension and cardiovascular disease in patients with end-stage kidney disease. RECENT FINDINGS: Factors such as anemia, valvular and vascular calcification, vasoconstrictors, uremic toxins, hypoglycemia, carbamylated proteins, oxidative stress, and inflammation have all been associated with the progression of cardiovascular disease in end-stage kidney disease but the causality of these mechanisms has not been proven. The high risk of cardiovascular mortality has not improved as in the general population despite many advancements in cardiovascular care over the last two decades. Mechanisms that increase hypertension risk in these patients are centered on the control of extracellular fluid volume; however, over-correction of volume with dialysis can increase risks of intradialytic hypotension and death in these patients. This review presents both recent and classic work that increases our understanding of hypertension and cardiovascular disease in end-stage kidney disease.
PURPOSE OF REVIEW: In this article, we summarize recent advances in understanding hypertension and cardiovascular disease in patients with end-stage kidney disease. RECENT FINDINGS: Factors such as anemia, valvular and vascular calcification, vasoconstrictors, uremic toxins, hypoglycemia, carbamylated proteins, oxidative stress, and inflammation have all been associated with the progression of cardiovascular disease in end-stage kidney disease but the causality of these mechanisms has not been proven. The high risk of cardiovascular mortality has not improved as in the general population despite many advancements in cardiovascular care over the last two decades. Mechanisms that increase hypertension risk in these patients are centered on the control of extracellular fluid volume; however, over-correction of volume with dialysis can increase risks of intradialytic hypotension and death in these patients. This review presents both recent and classic work that increases our understanding of hypertension and cardiovascular disease in end-stage kidney disease.
Authors: Christopher T Chan; Tom Greene; Glenn M Chertow; Alan S Kliger; John B Stokes; Gerald J Beck; John T Daugirdas; Peter Kotanko; Brett Larive; Nathan W Levin; Ravindra L Mehta; Michael Rocco; Javier Sanz; Brigitte M Schiller; Phillip C Yang; Sanjay Rajagopalan Journal: Circ Cardiovasc Imaging Date: 2012-02-23 Impact factor: 7.792
Authors: Nicholas I Cole; Pauline A Swift; Feng J He; Graham A MacGregor; Rebecca J Suckling Journal: J Hum Hypertens Date: 2018-11-09 Impact factor: 3.012
Authors: Andrew Smyth; Martin J O'Donnell; Salim Yusuf; Catherine M Clase; Koon K Teo; Michelle Canavan; Donal N Reddan; Johannes F E Mann Journal: Am J Hypertens Date: 2014-02-07 Impact factor: 2.689